Logo image of VTGN

VISTAGEN THERAPEUTICS INC (VTGN) Stock Fundamental Analysis

NASDAQ:VTGN - Nasdaq - US92840H4002 - Common Stock - Currency: USD

2.24  -0.01 (-0.44%)

Fundamental Rating

3

Taking everything into account, VTGN scores 3 out of 10 in our fundamental rating. VTGN was compared to 563 industry peers in the Biotechnology industry. VTGN has a great financial health rating, but its profitability evaluates not so good. VTGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VTGN has reported negative net income.
VTGN had a negative operating cash flow in the past year.
In the past 5 years VTGN always reported negative net income.
VTGN had a negative operating cash flow in each of the past 5 years.
VTGN Yearly Net Income VS EBIT VS OCF VS FCFVTGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -51.25%, VTGN is in line with its industry, outperforming 45.65% of the companies in the same industry.
VTGN has a Return On Equity of -58.31%. This is comparable to the rest of the industry: VTGN outperforms 59.86% of its industry peers.
Industry RankSector Rank
ROA -51.25%
ROE -58.31%
ROIC N/A
ROA(3y)-123.28%
ROA(5y)-157.78%
ROE(3y)-196.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTGN Yearly ROA, ROE, ROICVTGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

VTGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTGN Yearly Profit, Operating, Gross MarginsVTGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

More info and screens

7

2. Health

2.1 Basic Checks

VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTGN has been increased compared to 1 year ago.
Compared to 5 years ago, VTGN has more shares outstanding
VTGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VTGN Yearly Shares OutstandingVTGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
VTGN Yearly Total Debt VS Total AssetsVTGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.33, we must say that VTGN is in the distress zone and has some risk of bankruptcy.
VTGN has a Altman-Z score (-3.33) which is in line with its industry peers.
VTGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.33
ROIC/WACCN/A
WACC9.98%
VTGN Yearly LT Debt VS Equity VS FCFVTGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 9.35 indicates that VTGN has no problem at all paying its short term obligations.
VTGN has a Current ratio of 9.35. This is in the better half of the industry: VTGN outperforms 77.44% of its industry peers.
VTGN has a Quick Ratio of 9.35. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VTGN (9.35) is better than 77.62% of its industry peers.
Industry RankSector Rank
Current Ratio 9.35
Quick Ratio 9.35
VTGN Yearly Current Assets VS Current LiabilitesVTGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

VTGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.81%, which is quite impressive.
The Revenue for VTGN has decreased by -33.58% in the past year. This is quite bad
The Revenue has been decreasing by -0.80% on average over the past years.
EPS 1Y (TTM)56.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.09%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y-0.8%
Revenue growth 5YN/A
Sales Q2Q%-43.12%

3.2 Future

The Earnings Per Share is expected to grow by 22.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, VTGN will show a very strong growth in Revenue. The Revenue will grow by 200.60% on average per year.
EPS Next Y-8.71%
EPS Next 2Y-2.35%
EPS Next 3Y-5.2%
EPS Next 5Y22.38%
Revenue Next Year-33.04%
Revenue Next 2Y-36.33%
Revenue Next 3Y61.72%
Revenue Next 5Y200.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VTGN Yearly Revenue VS EstimatesVTGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 200M 400M 600M 800M 1B
VTGN Yearly EPS VS EstimatesVTGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VTGN. In the last year negative earnings were reported.
Also next year VTGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTGN Price Earnings VS Forward Price EarningsVTGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTGN Per share dataVTGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as VTGN's earnings are expected to decrease with -5.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.35%
EPS Next 3Y-5.2%

More info and screens

0

5. Dividend

5.1 Amount

VTGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VISTAGEN THERAPEUTICS INC

NASDAQ:VTGN (5/9/2025, 4:05:07 PM)

2.24

-0.01 (-0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)06-09 2025-06-09/amc
Inst Owners54.71%
Inst Owner Change0%
Ins Owners0.26%
Ins Owner Change0%
Market Cap64.65M
Analysts88
Price Target13.26 (491.96%)
Short Float %1.8%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3%
Min EPS beat(2)-5.58%
Max EPS beat(2)11.57%
EPS beat(4)3
Avg EPS beat(4)13.41%
Min EPS beat(4)-5.58%
Max EPS beat(4)32.39%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.89%
Min Revenue beat(2)-19.67%
Max Revenue beat(2)27.45%
Revenue beat(4)1
Avg Revenue beat(4)-17.38%
Min Revenue beat(4)-72.55%
Max Revenue beat(4)27.45%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.11%
EPS NY rev (1m)0%
EPS NY rev (3m)5.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)16.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.58
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS0.02
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.25%
ROE -58.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.28%
ROA(5y)-157.78%
ROE(3y)-196.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.26%
Cap/Sales 18.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.35
Quick Ratio 9.35
Altman-Z -3.33
F-Score2
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)101.87%
Cap/Depr(5y)107.79%
Cap/Sales(3y)38.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.09%
EPS Next Y-8.71%
EPS Next 2Y-2.35%
EPS Next 3Y-5.2%
EPS Next 5Y22.38%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y-0.8%
Revenue growth 5YN/A
Sales Q2Q%-43.12%
Revenue Next Year-33.04%
Revenue Next 2Y-36.33%
Revenue Next 3Y61.72%
Revenue Next 5Y200.6%
EBIT growth 1Y-55.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.16%
OCF growth 3YN/A
OCF growth 5YN/A